08-12-04

Docket No. 60004 (72021)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U. Herzberg et al.

Serial No.:

10/718,034

Examiner: To be determined

Filed:

November 19, 2003

Group Art Unit: 1617

For:

COMBINATION THERAPY FOR THE TREATMENT OF PAIN

# CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service in an envelope as "Express Mail Post Office Addressee," Mailing Label No. EV437818054US, addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on August 10, 2004.

Sir:

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

#### I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

#### II. **COPIES**

a. 🛛

Submitted herewith is a legible copy of (i) each U.S and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.

### CONCISE EXPLANATION OF THE RELEVANCE III.

(check at least one box)

a. 🛛


Except as may be indicated below in (b), all of the patents, publications or other information are in the English language or were cited in an English language Search Report, a copy of which is attached hereto

(concise explanation not required).

	b. 🗌	A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:				
	c. 🛚	The following additional information is provided for the Examiner's consideration:				
		See Search Report dated June 9, 2004.				
		<u>FEES</u>				
IV.	THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b) (check one box)					
	a. 🗌	within three months of the filing date of a national application (37 C.F.R. § 1.97(b) (1)). No fee or certification is required.				
	b. 🗌	within three months of the date of entry of the national stage as set forth in §1.491 in an international application (37 C.F.R. § 1.97(b) (2)). No fee or certification is required.				
	c. 🛚	before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b) (3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e)below, or, if no certification has been made, charge our deposit account a fee in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).				
V.	THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c): (check one box)					
	before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c) (1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c) (2)).					
	a. No ce	ertification; therefore, a fee in the amount of \$180.00 is required by 37 C.F.R § 1.17(p).				
	b. See t	or he certification below. No fee is required.				
VI.	<u>CERTIFICA'</u>	TION UNDER 37 C.F.R. § 1.97(e) (check only one box)				
The undersigned hereby certifies that						
	a. 🛚	each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart				

	foreign application n of this IDS; or	ot more than three months prior to the filing					
b. 🗌	communication from foreign application of reasonable inquiry, v	on contained in the IDS was cited in a a foreign Patent Office in a counterpart r, to the best of my knowledge after making was known to any individual designated in 37 than three months prior to the filing of this					
с. 🗌	from a foreign Patent undersigned certifies the IDS was cited in in a counterpart fore prior to the filing of the undersigned here information contained from a foreign Patent to the best of my known to any individual	information were cited in a communication of Office. As to this information, the that each item of information contained in a communication from a foreign Patent Office ign application not more than three months his IDS. As to the remaining information, eby certifies that no item of this remaining ed in the IDS was cited in a communication of Office in a counterpart foreign application or, owledge after making reasonable inquiry, was lual designated in 37 C.F.R. § 1.56(c) more rior to the filing of this statement.					
	Please charge Deposit Account No. 04-1105 in the amount of \$ for the above-indicated fee. A triplicate copy of this paper is attached.						
$\boxtimes$	No fee is required.						
	Fee enclosed, check in the amount of \$ 180.00.						
If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition, if necessary) and charge the appropriate fee to Deposit Account No. 04-1105.							
	Respectfully submitted,						
	_	MRAGA					
Date: Augus	Ī	John B. Alexander (Reg. No. 48,399) DWARDS & ANGELL, LLP					
Tel. No. (617		№ O. Box 55874 Boston, MA 02205					

BOS2\_449107.1



							Page 1 of 1		
FORM PTO-1449			l l	DOCKET NO.: 60004 (72021)		SERIAL NO.: 10/718,034			
INFORMATI	ON D	ISCLOSURE STATEMEN	T APPLICA	APPLICANT(S): U. Herzberg et al.					
			FILING	DATE: Novembe	r 19, 2003	GROUP NO.: 1617			
			FOREIG	N PATENT DOC	JMENTS				
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO		
	ВА	WO 02/08221 A	01/2002	РСТ					
	вв	WO 03/074520 A	09/2003	PCT					
	ВС	WO 03/080578 A	10/2003	PCT					
		OTHER DOCUMENTS (IN	ICLUDING	AUTHOR, TITLE	, DATE, PI	ERTINENT PAGES	s, etc.)		
	CA Del Arco et al., "Attenuation of spontaneous opiate withdrawal in mice by the anandamide transport inhibitor AM404," European Journal of Pharmacology 454:103-104 (2002).								
	CB Goldstein et al., "Adjuncts to opioid therapy," JAOA 102:S15-S21 (2002).								
		Caterina et al., "The Vanilloid Receptor: A Molecular Gateway to the Pain Pathway," Annu. Rev. Neurosci. 24:487-517 (2001).							
		·							
Examiner:		and the state of t				Date:			